News
1d
Zacks Investment Research on MSNEMA Accepts GSK's Filing for Expanded Use of RSV Vaccine ArexvyGSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to ...
Sales of the vaccine have been declining due to weak demand trends in China amid an economic slowdown. Gardasil sales ...
GSK RSV vaccine Arexvy accepted for regulatory review by EMA to expand use in adults 18 years, older
London: GSK plc has announced that the European Medicines Agency (EMA) has accepted the company's regulatory application to ...
GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...
Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around ...
Pfizer's RSV shot Abrysvo was cleared by the FDA last October for the 18 to 59 age group, extending its 2023 approval in the ...
The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a ...
Drugmaker GSK said on Friday that its RSV vaccine, Arexvy, has been accepted for regulatory review by the European Medicines ...
OPEN The FTSE 100 was expected to open 38.4 points lower ahead of the bell on Friday after closing 0.23% higher in the ...
LONDON, UK I June 13, 2025 I GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted the company’s regulatory ...
The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results